Welcome to our dedicated page for Amgen news (Ticker: AMGN), a resource for investors and traders seeking the latest updates and insights on Amgen stock.
Amgen Inc. reports developments across its biotechnology medicines business, including discovery, development, manufacturing and delivery of human therapeutics. Company updates center on a portfolio and pipeline spanning cancer, inflammatory conditions, rare diseases, heart disease, obesity and obesity-related conditions, with named products and programs such as TEPEZZA, Repatha and IMDELLTRA appearing in clinical and commercial announcements.
Recurring news also covers quarterly financial results, non-GAAP performance measures, manufacturing network investments, supply-chain capacity, research collaborations, medical and investor conference presentations, and executive or organizational changes tied to the integration of biology, technology, artificial intelligence and data across Amgen's operations.
Bristol Myers Squibb (NYSE:BMY) is highlighted in a broader look at AI-driven cardiology and novel cardiac therapies. The company reported positive Phase 3 SCOUT-HCM results for Camzyos in adolescents with obstructive hypertrophic cardiomyopathy, meeting the primary endpoint with a -48.0 mm Hg Valsalva LVOT gradient difference vs placebo (P < 0.0001).
No patients experienced left ventricular ejection fraction below 50%. Camzyos is already approved for adult oHCM in over 60 countries and prescribed to more than 22,000 U.S. patients, positioning BMY to potentially seek a pediatric label expansion in a population without targeted therapies.
Amgen (NASDAQ:AMGN) will present at the Bank of America Merrill Lynch Global Healthcare Conference on Wednesday, May 13, 2026 at 10:00 a.m. PT. Presenters are Peter Griffith (EVP & CFO) and Jay Bradner (EVP, R&D). The presentation will be webcast and archived for at least 90 days.
Webcast access, timing and links are available on Amgen's Investor Relations Events Calendar on the company website.
Amgen (NASDAQ: AMGN) announced an additional $300 million U.S. manufacturing investment on May 4, 2026, focused on expanding its biologics facility in Juncos, Puerto Rico. This addition and prior commitments bring Amgen's announced U.S. manufacturing investments over the last year to nearly $2 billion.
The Juncos expansion targets next‑generation technologies, increased production capacity, workforce development and hundreds of construction jobs, and builds on recent investments in Ohio, California and North Carolina.
Amgen (NASDAQ:AMGN) reported Q1 2026 results: total revenue $8.6B, +6% YoY, product sales $8.218B (+4%), GAAP EPS $3.34 (+4%), and non-GAAP EPS $5.15 (+5%).
GAAP operating margin rose to 32.4%; non-GAAP margin was 45.3%. Free cash flow was $1.5B. Full-year 2026 guidance: revenue $37.1B–$38.5B, GAAP EPS $15.62–$17.10, non-GAAP EPS $21.70–$23.10; share repurchases not to exceed $3.0B.
Amgen (NASDAQ:AMGN) reported Q1 2026 results: total revenues $8.6B (+6%), GAAP EPS $3.34 (+4%) and non-GAAP EPS $5.15 (+5%). Product sales grew 4% with 16 brands in double-digit growth. Free cash flow was $1.5B. Full‑year 2026 guidance: revenues $37.1B–$38.5B; non‑GAAP EPS $21.70–$23.10.
Amgen (NASDAQ:AMGN) will report first quarter 2026 financial results on Thursday, April 30, 2026, after the U.S. market close. A conference call with management, including CEO Robert A. Bradway, will follow at 4:30 p.m. ET.
Live audio will be webcast on Amgen's investor site and archived for at least 90 days. Presentation times and webcast links are listed on Amgen's Investor Relations Events Calendar.
Amgen (NASDAQ:AMGN) announced the retirement of David M. Reese, executive vice president and Chief Technology Officer, effective June 30, 2026. The company will implement organizational changes on June 1, 2026 to deepen integration of biology, data science, and AI across R&D and commercial functions.
James Bradner will lead R&D, Artificial Intelligence and Data; Sean Bruich becomes senior vice president, Chief Technology Officer; Murdo Gordon is executive vice president, Amgen Global Markets and Policy; Paul Burton remains chief medical officer.
Amgen (NASDAQ: AMGN) announced positive topline Phase 3 results for subcutaneous TEPEZZA (teprotumumab-trbw) delivered via an on-body injector in adults with moderate-to-severe active Thyroid Eye Disease (TED).
The trial met its primary endpoint with a 76.7% proptosis response vs. 19.6% placebo and a mean proptosis reduction of -3.17 mm vs. -0.80 mm placebo at week 24 (both p<0.0001). Safety was consistent with IV TEPEZZA; common adverse events (≥10%) included muscle spasms, tinnitus, weight decrease, ear discomfort, nausea and diarrhea.
Zai Lab and Amgen (NASDAQ: AMGN) announced a global clinical trial collaboration to test Zai Lab’s DLL3-targeting ADC, zocilurtatug pelitecan (zoci), combined with Amgen’s FDA-approved Bispecific T-cell Engager IMDELLTRA® in extensive-stage small cell lung cancer (ES-SCLC).
Amgen will sponsor and lead a global Phase 1b study to evaluate safety and efficacy; Zai Lab will retain full ownership of zoci and supply the study drug. Prior Phase 1/2 data showed high response rates and strong intracranial activity for zoci.
Amgen (NASDAQ:AMGN) reported that Repatha (evolocumab) reduced first major adverse cardiovascular events by 31% in a high-risk primary prevention subgroup from VESALIUS-CV.
The analysis (3,655 patients with diabetes, median 4.8 years) showed median LDL-C 44 mg/dL at 96 weeks versus 105 mg/dL for placebo; results were presented at ACC and published in JAMA.